Literature DB >> 23681068

ALS-associated mutations in FUS disrupt the axonal distribution and function of SMN.

Ewout J N Groen1, Katsumi Fumoto, Anna M Blokhuis, Jooyeon Engelen-Lee, Yeping Zhou, Dianne M A van den Heuvel, Max Koppers, Femke van Diggelen, Jessica van Heest, Jeroen A A Demmers, Janine Kirby, Pamela J Shaw, Eleonora Aronica, Wim G M Spliet, Jan H Veldink, Leonard H van den Berg, R Jeroen Pasterkamp.   

Abstract

Mutations in the RNA binding protein fused in sarcoma/translated in liposarcoma (FUS/TLS) cause amyotrophic lateral sclerosis (ALS). Although ALS-linked mutations in FUS often lead to a cytosolic mislocalization of the protein, the pathogenic mechanisms underlying these mutations remain poorly understood. To gain insight into these mechanisms, we examined the biochemical, cell biological and functional properties of mutant FUS in neurons. Expression of different FUS mutants (R521C, R521H, P525L) in neurons caused axonal defects. A protein interaction screen performed to explain these phenotypes identified numerous FUS interactors including the spinal muscular atrophy (SMA) causing protein survival motor neuron (SMN). Biochemical experiments showed that FUS and SMN interact directly and endogenously, and that this interaction can be regulated by FUS mutations. Immunostaining revealed co-localization of mutant FUS aggregates and SMN in primary neurons. This redistribution of SMN to cytosolic FUS accumulations led to a decrease in axonal SMN. Finally, cell biological experiments showed that overexpression of SMN rescued the axonal defects induced by mutant FUS, suggesting that FUS mutations cause axonal defects through SMN. This study shows that neuronal aggregates formed by mutant FUS protein may aberrantly sequester SMN and concomitantly cause a reduction of SMN levels in the axon, leading to axonal defects. These data provide a functional link between ALS-linked FUS mutations, SMN and neuronal connectivity and support the idea that different motor neuron disorders such as SMA and ALS may be caused, in part, by defects in shared molecular pathways.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23681068     DOI: 10.1093/hmg/ddt222

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  71 in total

Review 1.  The pathogenicity of splicing defects: mechanistic insights into pre-mRNA processing inform novel therapeutic approaches.

Authors:  Elisabeth Daguenet; Gwendal Dujardin; Juan Valcárcel
Journal:  EMBO Rep       Date:  2015-11-13       Impact factor: 8.807

Review 2.  Characteristics of circular RNAs generated by human Survival Motor Neuron genes.

Authors:  Eric W Ottesen; Ravindra N Singh
Journal:  Cell Signal       Date:  2020-06-15       Impact factor: 4.315

Review 3.  Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era.

Authors:  Ximena Paez-Colasante; Claudia Figueroa-Romero; Stacey A Sakowski; Stephen A Goutman; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2015-04-21       Impact factor: 42.937

Review 4.  Developing therapies for spinal muscular atrophy.

Authors:  Mary H Wertz; Mustafa Sahin
Journal:  Ann N Y Acad Sci       Date:  2015-07-14       Impact factor: 5.691

5.  Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease.

Authors:  Natalia Rodriguez-Muela; Nadia K Litterman; Erika M Norabuena; Jesse L Mull; Maria José Galazo; Chicheng Sun; Shi-Yan Ng; Nina R Makhortova; Andrew White; Maureen M Lynes; Wendy K Chung; Lance S Davidow; Jeffrey D Macklis; Lee L Rubin
Journal:  Cell Rep       Date:  2017-02-07       Impact factor: 9.423

Review 6.  Genetics of Amyotrophic Lateral Sclerosis.

Authors:  Mehdi Ghasemi; Robert H Brown
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 7.  The role of FUS gene variants in neurodegenerative diseases.

Authors:  Hao Deng; Kai Gao; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2014-05-20       Impact factor: 42.937

Review 8.  Advances in therapy for spinal muscular atrophy: promises and challenges.

Authors:  Ewout J N Groen; Kevin Talbot; Thomas H Gillingwater
Journal:  Nat Rev Neurol       Date:  2018-02-09       Impact factor: 42.937

Review 9.  mRNP assembly, axonal transport, and local translation in neurodegenerative diseases.

Authors:  Bilal Khalil; Dmytro Morderer; Phillip L Price; Feilin Liu; Wilfried Rossoll
Journal:  Brain Res       Date:  2018-02-17       Impact factor: 3.252

Review 10.  Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.

Authors:  Vittoria Pagliarini; Piergiorgio La Rosa; Claudio Sette
Journal:  Hum Genet       Date:  2017-04-22       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.